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ABSTRACT 
Luma Essaid: The Role of Hepatocyte Growth Factor in Obesity-induced Basal-like Breast 
Cancer 
(Under the direction of Liza Makowski) 
Obesity is a well-known modifiable risk factor for many diseases, including cancer. Recent 
studies in mice and humans have demonstrated the significance of the microenvironment in 
shaping cancer risk and progression. This study investigated the obesity-induced hepatocyte 
growth factor (HGF)/cMET signaling pathway in promoting basal-like breast cancer (BBC), an 
aggressive triple negative subtype of breast cancer with no targeted therapy. HGF is a secreted 
protein released from stromal cells in an inactive form. Once activated, HGF binds to its receptor 
cMET, a proto-oncogene, which activates pro-tumor signaling pathways. We have previously 
demonstrated that obesity increases HGF/cMET in murine mammary glands and drives early 
tumor onset in a genetically engineered mouse model (GEMM) of human BBC, C3(1)-Tag mice. 
To test our hypothesis that weight loss would reverse the effects of obesity, mice were weaned at 
3 weeks of age onto either a low fat (10% kcal from fat) or high fat (60% kcal from fat) diet. We 
sought to investigate changes in the pro-tumor pathway after a diet switch at 10 weeks of age, 
from 60% kcal from fat to 10%, by inducing weight loss prior to tumor onset. Importantly, 
HGF/cMET expression in normal mammary glands, and cMET in tumors, was elevated with 
obesity and was significantly reversed with weight loss. This study also quantified adipocyte area 
in normal mammary and tumor tissue between the 10% kcal from fat and 60% kcal from fat diets 
to study diet effects on adipocyte size. Interestingly, many of the HGF/cMET regulators, e.g., 
activators such as HGF-Activator, and inhibitors such as HGF-Activator Inhibitor were modified 
in the weight-loss mice between Normal Associated Fibroblasts and Cancer Associated 
Fibroblasts. Finally, we confirmed that C3(1)-Tag mammary tumor epithelial cells grown in 
conditioned media from fibroblasts of differing diets, 10% and 60% kcal from fat, have 
distinctive proliferation indices. In summary, these results indicate that low and high fat diets 
have differential effects on murine phenotypes, including body weight, body composition, and 
stromal microenvironment. Importantly, weight loss in adulthood is possible, which reversed the 
obesity-mediated pro-tumorigenic pathway. Future research aims include implementing weight 
loss as a preventative measure in human subjects and inhibiting the HGF/cMET pathway to 
evaluate potential treatment for obesity-driven BBC. 
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STUDY AIMS AND HYPOTHESIS 
In the current study we investigated the effects of obesity on the development of basal-like breast 
cancer through the Hepatocyte Growth Factor (HGF)/cMET pathway. We hypothesized that 
obesity-associated changes in the mammary microenvironment, particularly the increase in 
stromal HGF secretion, lead to alteration in tumor profile, proliferation, and aggression. Past 
studies in our lab have shown that mammary glands isolated from obese mice contained higher 
levels of HGF compared to normal mammary from lean mice, as well as a decrease in tumor 
latency, the time to develop a tumor (Sundaram 2013). This leads us to question the effects of 
this distinct finding, as HGF is a growth factor known to be involved in cell growth, motility, and 
proliferation (Blumenschein 2012). We aimed to study the effects of weight status on the 
development of basal-like breast cancer, a specific molecular subtype that currently has no 
targeted therapy. In this study, we proposed that HGF and its receptor cMET play a significant 
role in obesity-mediated breast cancer development.  
 To study this hypothesis, this project examined the HGF/cMET signaling pathway. Using 
a genetically engineered mouse model (GEMM) that most resembles human basal-like breast 
cancer (Sundaram 2013), C3(1)-Tag mice were exposed to low and high fat diets to generate 
mice that were lean or obese (as defined by a doubling of adiposity) in order to compare the 
differences in HGF/cMET protein levels. First, we studied the effects of reversing the observed 
obesity phenotype on tumor latency and progression (Sundaram 2013) by inducing weight loss 
through diet switch from high to low fat diet. Second, we studied the HGF/cMET pathway and 
its mediators by measuring the expression of genes that regulate this pathway in normal 
mammary and tumor murine tissue. Finally, we studied the differing effects of conditioned 
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media derived from fibroblasts isolated from lean and obese normal mammary gland on 
proliferation of basal-like breast cancer epithelial cells.   
 
SPECIFIC AIMS 
AIM 1: To study the effect of reversing the obesity phenotype in mice genetically 
engineered to develop basal-like breast cancer. 
 
HYPOTHESIS: Mice in the diet switch group, from high fat diet (60% kcal from fat) to low fat 
diet  (10% kcal from fat), will have lower HGF and cMET protein levels than obese; thus, 
weight-loss mice will reverse these obesity-related markers.  
 
RATIONALE: Weight-loss indicates loss of body weight and fat mass and thus results in an 
alteration of the microenvironment from one of an obese phenotype to one that is lean. Recent 
epidemiologic studies demonstrate that, in obese individuals, plasma HGF is elevated more than 
three-fold compared to lean individuals and this elevation can be reversed with drastic weight-
loss, as in bariatric surgery (Bell 2006). As obesity is one of the limited modifiable risk factors 
for BBC, we wanted to further understand how weight reduction through a dietary intervention 
would affect BBC development and progression.  
 
EXPERIMENTAL DESIGN: 
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Figure 1. Diet-switch study design. C(3)1-Tag mice were weaned at 3 weeks of age onto either 
(1) low fat (10% kcal from fat, n=15) or (2) high fat (60% kcal from fat, n=30) diets. At 10 
weeks of age, n=15 mice from high fat diet (HFD) were switched to low fat diet (LFD), creating 
the 60->10% diet group. Mice were observed weekly for body weight, and MRI analysis for 
body composition that was conducted where time points are indicated by the arrows in the figure 
(weeks 3, 10, 12, and 14). Tumor occurrence was monitored weekly. After palpation of first 
tumor, tumor volume was measured with calipers every 2 days to measure tumor progression. 
Mice were sacrificed 3 weeks after occurrence of first tumor, where tumor number was also 
determined and tissues (mammary, tumor, adipose, brain, liver, and spleen) were collected.  
- Start experiment with 2 mouse groups, low (n=15) and high (n=30) fat diet 
- Wean mice onto respective diet at 3 weeks of age  
- At 10 weeks, half (n=15) of high fat diet mice will switch to low fat diet 
- Measure body weight weekly throughout the study to track weight gain and/or loss 
- Use MRI to determine body composition  
- Collect mammary glands and tumors at sacrifice, (3 weeks after latency) 
- Analyze adipocyte size in mammary gland microenvironment 
- Use Immunohistochemistry (IHC) to measure HGF and cMET in mammary glands and 
tumors 
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AIM 2: To determine the effect of normal versus cancer associated fibroblasts on the 
expression of genes involved in the hepatocyte growth factor/cMET pathway and its 
regulation using quantitative PCR in isolated, primary fibroblasts 
 
HYPOTHESIS: In accordance with the recent findings that HGF is elevated in serum of obese 
patients, the expression of genes involved in producing high levels of functional HGF (e.g., 
HGF-Activator, HGF-A) will be significantly higher in obese mice compared to lean mice, 
whereas the expression of genes involved in reducing levels of functional HGF (e.g., HGF-
Activator-Inhibitor, HGF-AI) is expected to be higher in lean mice. In addition, the expression of 
genes that promote HGF (HGF, HGF-A) levels will be higher in cancer associated fibroblasts 
compared to normal associated fibroblasts.  
 
RATIONALE: As there are higher levels of serum HGF protein in obese compared to lean 
mice, we expect that the expression of HGF-A that would produce greater levels of HGF would 
also be significantly higher compared to lean mice with lower HGF levels. In addition, as HGF-
AI is responsible for inhibiting the activator, we expect this expression to be greater in lean mice 
(lower in obese). Additionally, as CAFs are associated with the activation of the tumorigenic 
pathway, we expect that the expression of genes that promote HGF and the resulting oncogenic 
pathway will be higher compared to NAFs. 
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Figure 2. HGF/cMET pathway. HGF binding to cMET activates an oncogenic and proliferative 
pathway, including anti-apoptosis and angiogenesis. HGF-A is a protease that cleaves HGF into 
its active form. HGF-AI inhibits the action of HGF-A, thus inhibiting the proliferative pathway. 
 
EXPERIMENTAL DESIGN:  
- Collect mammary glands, tumors, and isolate primary fibroblasts (from normal mammary 
and tumors) for culture at sacrifice 
- Extract RNA from normal and cancer associated fibroblasts  
- Complete quantitative PCR to measure expression of HGF, HGF-A, and HGF-AI in 
primary fibroblasts  
 
AIM 3: Determine whether secreted factors in media from isolated, primary fibroblasts of 
obese and lean mice impact the proliferation of an epithelial tumor cell line derived from a 
mammary tumor from a C3(1)-Tag mouse.   
 
HYPOTHESIS: C3(1)-Tag epithelial tumor cells collected from mammary tumors that are 
supplemented with conditioned media derived from a primary culture of fibroblasts derived from 
normal mammary glands of obese mice, those fed high fat diet (60% kcal from fat), will have a 
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higher proliferation index than the same cells supplemented with conditioned media from lean 
mice, those fed a 10% kcal from fat diet. 
 
RATIONALE  
As obesity increases HGF in vivo and ex vivo, we sought to investigate whether conditioned 
media from normal associated fibroblasts produce any proliferative effect of secreted factors by 
measuring the proliferation index of an epithelial tumor cell line derived from a mammary tumor 
from a C3(1)-Tag mouse using a BrdU assay. 
 
EXPERIMENTAL DESIGN:  
- Plate Luciferase expressing C3(1)-Tag epithelial tumor cells in a 96-well plate and allow 
cells to attach over night.  
- Add conditioned media from 7 different NAF isolations and incubate for 18 hours 
- Add BrdU and incubate an additional 6 hours. 
- Determine proliferation index by measuring the amount of BrdU incorporation 
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II.  INTRODUCTION 
Obesity and overweight is increasingly threatening health worldwide. According to the World 
Health Organization, in 2014 there were more than 1.9 billion adults, 18 years and older, who 
were overweight, with 600 million of these adults classified as obese (WHO 2015). The United 
States is battling an obesity epidemic, as more than two-thirds of the population over the age of 
20 years is overweight or obese. Overall, these statistics account for a substantial portion of 
global morbidity and mortality, as well as incidence of several types of cancer (Kruijsdijk 2009). 
Not all Americans are affected equally -  rates of overweight and obesity are higher for African 
Americans and Hispanic women  than Caucasian, and higher for Hispanic men than Caucasian 
and African American; additionally, rates tend to increase with age (Ogden 2014). These data on 
disparities of weight status and global mortality and morbidity emphasize the need to further 
understand the detrimental effects of obesity. 
A serious consequence of the obesity epidemic is the association of obesity with breast 
cancer risk, as it is the most common cancer in women and second most common cause of death 
(CDC 2014). Breast cancer is a heterogeneous disease composed of a growing diversity of 
subtypes. Recent gene expression profiling by Carey, et al., from the Carolina Breast Cancer 
Study, a population-based case control study of African-American and white women in North 
Carolina, identified breast cancer “intrinsic” subtypes, including: estrogen-receptor positive 
(luminal) tumors, two separate groups of ER-negative tumors (basal-like and human epidermal 
growth factor receptor 2 (HER2)-positive), normal-like, and others (Carey 2006) (Millikan 
2008).  
Of these subtypes, basal-like breast cancer (BBC) does not have a targeted therapy, as it 
is typically estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
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factor receptor 2 (HER-2) negative. Basal-like refers to the tumors that have cells with features 
similar to the basal cells surrounding the mammary ducts. It should be noted that BBC refers to a 
specific gene expression profile, as shown in microarray analysis (Carey 2006) (Herschkowitz 
2007). Not all basal-like tumors lack ER, PR, and HER2 receptors, and similarly, not all “triple-
negative” cancers show a basal-like phenotype (Bertucci 2008). The BBC subtype represents 
about 15 to 20 percent of breast cancers and occur disproportionately more often in younger 
women and African American women (Millikan 2008). There appear to be "windows of 
susceptibility”, or periods when obesity creates an increased risk for the development of breast 
cancer (Makowski 2013). In the case of BBC, epidemiological studies demonstrate that obesity 
heightens risk in both pre- and post-menopausal women (Millikan 2008). As BBC is highly 
aggressive and results in poor prognosis (Carey 2006), and as obesity is a modifiable risk factor, 
understanding the role of obesity in BBC development is vital for the creation of public health 
preventative strategies.  
Recent studies have demonstrated the significance of hepatocyte growth factor (HGF) 
and cMET in promoting BBC. HGF is a protein, specifically a cytokine and multifunctional 
growth factor, released from stromal cells in an inactive form. Once activated by a serine 
protease, such as HGF-Activator (HGF-A), it can bind to its receptor cMET, a trans-membrane 
receptor tyrosine kinase. Ultimately, this leads to the multistep “invasive growth” pathway that 
includes activation of signaling pathways that result in increased growth, proliferation, 
invasiveness and angiogenesis (Blumenschein 2012). The serine protease HGF-A is also 
regulated upstream by two tumor-suppressor pathways, HGF-Activator-Inhibitor (HGF-AI) type 
1 and type 2, which are serine protease inhibitors that act as pseudo substrates to HGF-A, 
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inhibiting the function of HGF-A and decreasing the amount of active HGF,  thus disturbing the 
HGF/cMET pathway.  
This precise regulation of the HGF/cMET pathway is vital for normal cell function and 
prevention of tumorigenesis. However, in BBC, HGF/cMET signaling contributes to 
oncogenesis and promotes aggressive tumor progressiveness (Cecchi 2012). In addition, it is 
established that obese patients have significantly higher serum levels of HGF than their lean 
counterparts (Rehman 2003). In light of this fact, and the demonstrated increased risk of BBC in 
obesity, it is imperative to study the HGF/cMET pathway in relation to weight status and 
proliferative effects on mammary epithelium. We hypothesize that weight-loss or intake of a low 
fat diet (10% kcal from fat) will reduce the amount of HGF secreted, modify levels of its 
regulators, and decrease HGF-induced proliferative effects.  
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III.  METHODS  
 
Animals and diets  
Animal studies were performed with approval and in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. 
Female C3(1)-Tag mice were obtained in collaboration with the UNC Lineberger 
Comprehensive Cancer Center (LCCC) Mouse Phase I Unit (MP1U). C3(1)-Tag mice (Green 
2000) were used to study the role of diet on BBC, as these mice were shown to be highly 
representative of human basal-like tumors (Herschkowitz 2007). In females, the simian virus 
(SV40) large tumor antigen (Tag) is expressed in the distal mammary ductal epithelium and 
terminal ductal lobular unit in a hormone-independent manner leading to the development of 
mammary tumors in female mice (Green 2000). C3(1)-Tag mice were generated by crossing 
heterozygous male mice with FVB/N non- transgenic female mice. Diets obtained from Research 
Diets Inc. (New Brunswick, NJ, USA) were matched for protein, vitamins, and minerals, and 
provided 10% kcal (“10%”); and 60% kcal (“60%”) derived from fat. Details of the diet 
components are provided in Sundaram et al. (Sundaram 2013).  
 
Body weight and composition 
Body weight was measured prior to starting mice on diet and weekly until sacrifice. Body 
composition including lean mass, fat mass, free water content, and total water content of non- 
anesthetized mice was also measured at 0, 10, 12, and 14 weeks, and at sacrifice on diet using the 
EchoMRI-100 quantitative magnetic resonance whole body composition analyzer (Echo Medical 
Systems, Houston, TX, USA). Obesity is defined as greater than a 5% incremental increase in fat 
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composition. Fat mass is presented as percent fat mass over total body weight (Sundaram 2013) 
(Sundaram 2014).  
 
Tumor number and progression (change in volume) 
As described in Sundaram et al. (Sundaram 2013), mice were monitored for tumor development 
by palpating three times weekly and tumor latency was defined as age at detection of first tumor. 
After detection of the first tumor, tumor volumes were measured weekly over 3 weeks using 
calipers to measure the width (short diameter) and length (long diameter) in millimeter for each 
tumor. The tumor volumes were calculated using the formula: length × width2×0.5. The percent 
change in volume over time (tumor progression), was calculated: (End volume – Start 
volume)/Start volume × 100. Tumor progression (percent change in volume) of only the first 
palpated tumor is presented. Percent change for n = 15 mice was averaged in each diet group. 
The total number of tumors per mouse was counted at sacrifice (Sundaram 2014). 
 
Tissue harvest  
Three weeks after detection of the first tumor, mice were anesthetized by an intraperitoneal (i.p.) 
injection of avertin (Fisher Scientific, Pittsburgh, PA, USA). Blood was collected by cardiac 
puncture into a tube with 10 µl of 0.05 mM EDTA (final conc). Plasma was separated by 
centrifuging blood at 500 × g for 5 min. Plasma was stored at −80°C. Mammary glands without 
palpable or visible tumors were collected as “normal,” although atypia of ductal epithelium could 
be present in C3(1)-Tag mice (13). Portions of the tissues were placed into a cassette and 
formalin fixed for immunohistochemical (IHC) analysis (Sundaram 2014). 
 
Antibodies 
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Anti-mouse HGF antibody that detects total HGF (both pro and cleaved) and anti-mouse cMet 
antibody that detects pro- and cleaved cMet were obtained from R&D Systems (Minneapolis, 
MN, USA) (Sundaram 2013) (Sundaram 2014).  
 
Immunohistochemical analyses in normal mammary glands and tumors  
Immunohistochemical analysis was performed for HGF and c- Met and following the protocol 
previously described in Sundaram et al. (Sundaram 2013). Anti- mouse HGF antibody and anti-
mouse cMet antibody were used at a dilution of 1:400 with secondary donkey anti-goat antibody 
(1:500; Jackson Immunoresearch; # 705-065-147). Following staining, slides were scanned into 
the Aperio Scanscope CS system (Aperio Technologies, Vista, CA, USA) at a magnification of 
20× and staining was quantified using the Aperio Imagescope software. The scanned slides were 
analyzed using the appropriate algorithms as described in Sundaram et al (Sundaram 2013). The 
Aperio Imagescope software positive pixel counts for diaminobenzidine (DAB) staining in the 
color deconvolution algorithm was completed for HGF and membrane IHC algorithm for cMet 
quantification (Sundaram 2013) (Polcz 2013) (Ruifrok 2001). Aperio digital analysis of DAB 
allows for no subjective bias in quantification. Due to our interest in the normal and tumor 
microenvironment, IHC (rather than Western immunoblots of total tissue lysates) and 
representative 40× images are presented. An n = 5 random areas from sections (n = 2 per mouse) 
were quantified and aver- aged per animal (n = 8 mice per diet exposure group for HGF and n=5 
for cMet for both normal mammary glands and tumors) (Sundaram 2014). 
Gene expression 
Gene expression was measured using semi-quantitative real-time PCR (qPCR). Expression of 
18S was used to standardize gene expression levels. All genes were quantitated using TaqMan 
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Assays-on-Demand (AOD). All reactions had a volume of 20 µl. AOD reactions contained 2 µl 
cDNA (20 ng/µl), 7 µl deionized water, 0.5 µl 18s, 0.5 µl AOD, and 10 µl SsoAdvanced 
Universal Probes Supermix (Bio-Rad Laboratories, Hercules, CA). Reactions were run at 95o C 
for 10 seconds then 60o C for 20 seconds for 40 cycles in a 7900HT Fast Real-Time PCR System 
(Life Technologies, Carlsbad, CA). Data were analyzed using SDS 2.4 software and the 
comparative ∆∆CT method. 
 
Adipocyte Area 
Adipocyte area was calculated from histologic analysis from normal mammary and tumor tissue 
in FVB mice that were fed a low fat (10% kcal from fat) or high fat (60% kcal from fat) diet. For 
each tissue sample, there are 2 sections from which 50 adipocyte cell diameters were measured 
in each. From each section, 2 regions were selected from which 25 adipocyte diameters were 
measured, for a total of 4 regions and 100 cell diameters. Quantification was then applied using 
the area of a circle !!! then graphing by distribution of percentages of adipocyte area per 1000 !!!.  
 
Cell Proliferation: BrdU Assay 
Following 8 h serum starvation, C3(1)-Tag cells were plated on a 96 well plate at a density of 
25,000 cells/well for BrdU and assayed at the end of 48 h incubation with the treatment 
conditions. Fibroblast conditioned media from 10%-NAF, 60%-NAF diluted 1:1 with fresh 
media was used to treat C3(1)-Tag cells to examine potential regulation of cell proliferation. 
Serum free media-treated cells were used as non-proliferating controls. Untreated cells was also 
used as a control. In addition, wells without cells were used as blank controls for testing BrdU 
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specificity. BrdU assay was performed as recommended by the manufacturer (Abcam, 
Cambridge, MA) (Sundaram 2013).  
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IV.  RESULTS 
 
Figure 1. Diet-switch (60->10%) induced weight-loss and loss of body fat, and returned 
tumor profile to that of lean (10% kcal from fat diet) C(3)1-Tag mice. (A) Body weight 
(grams) measured weekly from 3 weeks of age at weaning to sacrifice (determined 3 weeks after 
tumor latency in our three groups of mice) in low fat (10%), high fat (60%), and diet switch (60-
>10%). *P =0.001 from weeks 9 to end of study vs. 60%;  P = 0.01 from weeks 11 till 
sacrifice vs. 60%). (B) Body composition (g fat mass/g body weight) from MRI at 5 time points: 
weaning (3 weeks), diet switch/determination (10 weeks), 12 weeks, 14 weeks, and at sacrifice 
(3 weeks after tumor onset). *P <0.05 vs. both 60 and 60→10%; P <0.05 vs. 60%). n=15 in 
each diet group. (C) Tumor progression as defined as percent change in volume of the tumor 
from latency to sacrifice (3 weeks later). (* vs. 10% P =0.001 and vs. 60→10% P =0.0024). n = 
15 in each diet group. (D) Tumor number as determined at sacrifice, n=15 in each diet group. 
C.! D.!
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Figure 2. HGF and cMET levels measured by Immunohistochemistry (IHC) analysis in 
normal mammary and tumor tissue from C(3)1-Tag mice on 10%, 60%, and 60->10% 
diets. (A, B) HGF measurement in normal mammary and tumor tissue. HGF levels are 
elevated by high fat diet (60% kcal from fat) and reduced with weight loss through dietary 
intervention (60-10% kcal from fat). [* 10% (P = 0.0102) and 60 → 10% (P = 0.0031) vs. 60%]. 
(C) cMET measurement in normal mammary tissue. Obesogenic diet elevate concentrations 
of cMET and weight-loss reduce the concentration to levels of lean mice. [* 10% (P = 0.036) 
and 60 → 10% (P = 0.004) vs. 60%]. (D) cMET measurement in tumor tissue. cMET is 
elevated by obesity and reversed by weight loss. [* 10% (P = 0.043) and 60 → 10% (P = 0.019) 
vs. 60%]. 
A.! B.!
C.! D.!
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Figure 3. Levels of expression for HGF, HGF-Activator, and HGF-Activator Inhibitor 
from normal and cancer associated fibroblasts from C(3)1-Tag mice on the 60-10% diet. 
Hepatocyte Growth Factor (HGF) is expressed at a greater level in cancer associated fibroblasts 
(CAFs) compared to normal associated fibroblasts CAFs. The serine protease, HGF-Activator, is 
also expressed at a greater level in CAFs compared to NAFs. In contrast, HGF-AI is more highly 
expressed in NAFs versus CAFs. N=3-4 
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Figure 4. Adipocyte cell area in adipose tissue in normal mammary and tumor tissue in 
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10% and 60% FVB mice quantified by distribution of percentages of adipocyte area per 
1000 !!!. (A, B) Distribution of adipocyte size by area (!!!) from histologic analysis of 
normal and tumor associated mammary glands form FVB mice fed a low fat (10%) or high fat 
(60%) kcal derived from fat diet. 
 
Figure 5. Proliferation index of C3(1)-Tag cells after addition of conditioned media from 
normal associated fibroblasts (NAFs) of C(3)1-Tag mice fed low (10% kcal from fat) and 
high fat (60% kcal from fat) diets. Using BrdU incorporation as a marker of proliferation, 
C(3)1-Tag cells grown in conditioned media from 60% NAFs (n= 7) or 10% NAFs (n= 5).  
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Body Weight, Body Composition 
At 3 weeks of age, mice were weaned to one of two diets: low fat (10% kcal from fat,n= 15) or 
high fat (60% kcal from fat, n= 30) diet. Starting at 9 weeks, mice fed the high fat diet (HFD) 
had significantly different body weights than those fed low fat diets (LFD) (P=0.001). At 10 
weeks of age, half (n=15) of the mice were switched to a LFD. As is shown in Figure 1a, one 
week after the diet switch, the 60 -> 10 % diet switch group’s body weights were comparable to 
that of the low fat diet group, indicating complete weight loss. Following diet switch this 60-
>10% diet switch group had significantly different body weights (P=0.01) compared to the HFD 
mice from 11 weeks to the end of the study. 
 Body composition differed with diet (Figure 1b). At 3 weeks of age, before start of diet, 
all mice had the same body composition. At 10 weeks of age, all mice fed HFD , thus both the 
60% and 60->10% groups, had significantly greater body fat compared to the lean, LFD-fed 
mice (P=0.0008, 60→10 vs. 10%, and P<0.05, 60 vs. 10%). In just 2 weeks after the diet switch, 
the body composition and fat content for the 60->10% mice join the 10% mice, and remained 
comparable until sacrifice.   
Tumor Volume, Tumor Number 
Tumor progression is also modified by weight status in these C3(1)-Tag mice. As shown in 
Figure 1c, mice on the obesogenic HFD had significantly greater tumor volume change 
compared to mice on the control diet (P= 0.001). Interestingly, the diet switch 60->10% group 
exhibited identical tumor volume changes to the 10% group of mice,  i.e., drastically lower than 
mice fed high fat diet (P = 0.002). While diet plays an important role in tumor progression, 
Figure 1d displays that all mice had comparable tumor burden as determined at sacrifice. In 
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summary, weight loss significantly blunted tumor progression and returned tumor volume levels 
to those seen in mice consistently on LFD.   
HGF, cMET in normal mammary and tumor tissues 
HGF-positive staining was elevated in normal mammary tissue of mice fed HFD (P = 0.002) 
compared to mice on the LFD (Figure 2a). This finding was significantly reversed by weight 
loss in the 60->10% diet mice (P = 0.003) in normal mammary tissue. In tumors, as shown in 
Figure 2b, neither obesity nor weight loss affected HGF protein levels. In normal mammary 
tissues, similar to HGF, cMET levels are significantly elevated by obesity (P=0.04) compared to 
LFD controls, and also significantly reduced by weight loss (P=0.004, Figure 2c) compared to 
their obese counterparts. This trend is continued in tumor tissues (Figure 2d), as obesity 
significantly elevated cMET (P=0.04) compared to lean mice. Weight loss in the 60 -> 10% diet 
switch group reversed this, as cMET staining was comparable to lean mice and significantly 
different than mice fed HFD (P=0.02).  
HGF/cMET regulator gene expression by quantitative PCR 
On expression levels of HGF, HGF-A and HGF-AI, our data in Figure 3 establishes variance of 
regulation between normal mammary and tumor tissue. There is a trend of greater expression 
levels for HGF in cancer associated fibroblasts (CAFs) compared to normal associated 
fibroblasts (NAFs). Additionally, we see greater expression of HGF-A in CAFs versus NAFs, 
implying greater activation of HGF and increased pro-tumorigenic cMET signaling in tumors. 
Finally, there is a decrease in expression of HGF-AI in CAFs, suggesting decreased inhibition of 
the activator, further establishing deregulation and promotion of the proliferative HGF/cMET 
pathway.  
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Adipocyte Area 
Adipocyte diameters were measured in normal mammary and tumor tissue in FVB mice as 
shown in Figure 4. The distribution of adipocyte areas indicate that there are a greater number of 
small adipocytes (≤ 1000!!!!)!in mice fed low fat diet compared to the obesogenic diet. In 
addition, as adipocyte area progressed, there were a greater number of large adipocytes 
(> 1000!!!!)! in mice fed the obesogenic diet. This trend is parallel in both normal mammary 
and tumor tissue.  
Cell Proliferation 
The degree of proliferation was marked by BrdU incorporation into C(3)1-Tag cells from 
mammary tumors. Conditioned media was added from NAFs from C(3)1-Tag mice fed LFD vs 
HFD, as described in Figure 5.  
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V.  DISCUSSION 
This study evaluated the role HGF in obesity-induced BBC. The development of obesity is 
detrimental for several reasons, including increased risk for BBC for pre- and post-menopausal 
women. Using the C(3)1-Tag GEMM to represent basal-like breast cancer, mice were assigned 
to either a low or high fat diet during their adult years. Mice fed on the HFD gained more weight 
and adiposity than mice on the LFD. Interestingly, mice in the 60 ! 10% diet switch group, that 
initially consumed 7 weeks of HFD and then were subsequently switched to LFD, had reversal of 
body weight and adiposity, rapidly paralleling the lean mice. This suggests that losing weight 
and adiposity is achievable in a short time frame and during adulthood.  
Tumor progression is also shaped by high fat diet, as obesity increased tumor volume 
compared to lean controls. In addition, weight loss significantly blunted tumor progression, 
reversing or preventing the effects of the HFD-induced obesity earlier in life. Tumor burden, on 
the other hand, was not affected by weight status, as mice fed high and low fat diets had similar 
tumor numbers at sacrifice.  
Obesity alters the mammary microenvironment and stromal-epithelial interactions. In our 
C3(1)-Tag model mammary HGF protein concentrations were elevated by obesity and lowered 
by weight-loss to levels seen in lean mice. The levels of cMET are also determined by weight 
status in normal mammary and tumor tissue, as this protein is elevated by obesity and 
substantially elevated in obese tumors, yet is blunted by weight loss. Overall, these findings 
show that obesity-associated increases in the HGF/cMET pathway, which likely promotes 
growth, motility, angiogenesis, and proliferation in BBC, can be reversed by weight loss.  
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Based on these findings, that HFD-induced obesity increased tumor progression, we 
sought to investigate the gene expression of regulators of the HGF/cMET pathway. We studied 
normal- and cancer-associated fibroblasts from mammary gland of weight loss mice and 
interestingly found differences in regulator gene expression based on tissue type. HGF and HGF-
A gene expression are elevated in CAFs compared to NAFs, while HGF-AI gene expression is 
elevated in NAFs, suggesting increased active HGF and signaling through cMET in the C3(1)-
Tag tumor microenvironment as compared to normal mammary. Cancer associated fibroblasts 
promote the progression of breast cancer, possibly through HGF/cMET, as expression levels of 
HGF and HGF-A genes are greater than HGF-AI. In contrast, NAFs have greater expression 
levels of HGF-AI, which may ultimately inhibit activation of the HGF/cMET pathway.  
Next we assayed for a correlation between HGF/cMET expression levels and the 
increased tumor progression observed. Using BrdU incorporation as a signature of proliferation, 
we report an elevated proliferation index for C(3)1-Tag mammary tumor cells cultured with 
conditioned media from NAFs of HFD-fed mice compared to LFD-fed lean controls. We found 
that secreted factors from fibroblasts isolated from normal mammary gland of mice fed HFD 
have higher proliferation index than the lean counterparts, although not statistically significant, 
indicating the need to repeat the experiment with a larger sample size.  
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CONCLUSIONS 
The results of the current study suggest that secretion of growth factors that result in 
mammary tumor proliferation is increased by HFD-induced obesity, and that the obese 
microenvironment up-regulates expression and activation of growth factors. As HGF is an 
important growth factor that is widely known to promote proliferation by signaling through its 
receptor, cMET, these effects may be a result of increased HGF secretion in obesity.  
In sum, our data shows that the HGF/cMET pathway is a potential mediator of obesity-
induced basal-like breast cancer: Concentrations of HGF was elevated by obesity in normal 
mammary can be reversed by weight loss. Similarly, cMET concentrations were elevated by 
obesity in tumor and normal mammary tissue and was subsequently blunted by weight loss. 
Additionally, there are remodeling effects based on normal vs tumor tissue microenvironment, as 
gene expression levels of regulators of the HGF/cMET pathway vary between normal and cancer 
associated fibroblasts. This finding suggests a need for future experiments in assessing the 
expression and protein levels of these regulator genes between diets, to determine whether 
obesity changes the epigenetic profile and can alter expression of HGF regulators. Increased 
proliferation of C3(1)-Tag mammary tumor cells induced by conditioned media from HFD-
exposed fibroblasts suggests that even cells derived from high proliferative capacities are further 
regulated after the addition of media from a differing microenvironment. Future research on the 
proliferative capacity of cells grown in media derived from NAFs of weight-loss mice should 
help further clarify the weight-loss microenvironment profile. All in all, we have identified a 
potential pathway mediating obesity-driven BBC, an issue of great importance to public health as 
this highly aggressive subtype of breast cancer currently does not have a targeted therapy. 
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